---
layout: default
title: Apremilast
parent: 僅模型預測 (L5)
nav_order: 53
evidence_level: L5
indication_count: 10
---

# Apremilast
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Apremilast: From Psoriatic Arthritis to Migraine Disorder

## One-Sentence Summary

Apremilast (Otezla®) is an oral phosphodiesterase 4 (PDE4) inhibitor with regulatory approvals in the USA and other jurisdictions for psoriatic arthritis and plaque psoriasis, though it is not currently registered in Australia.
The TxGNN model predicts it may have potential in managing **Migraine Disorder** (prediction score: 98.66%),
however this is currently supported by **no clinical trials** and **no directly relevant published literature** — this prediction is model-generated and remains a hypothesis only.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Psoriatic arthritis / Plaque psoriasis (FDA-approved globally; not registered in Australia) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 98.66% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Apremilast is a novel oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) — the primary intracellular enzyme responsible for degrading cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells. By inhibiting PDE4, Apremilast raises intracellular cAMP concentrations, which suppresses the production of pro-inflammatory cytokines including TNF-α, IL-17, IL-23, and interferon-γ. This anti-inflammatory mechanism has been clinically validated in psoriatic arthritis and plaque psoriasis, both of which are driven by dysregulated Th1/Th17 immune activity.

The theoretical connection to migraine rests on the neurobiological role of PDE4 in the central nervous system. PDE4 is highly expressed in neurons and glial cells, including within the trigeminal system. In migraine pathophysiology, neurogenic inflammation — particularly within the trigeminovascular system — plays a central role. PDE4 inhibition could theoretically suppress this neuroinflammation via elevated cAMP, leading to downregulation of NF-κB signalling and modulation of calcitonin gene-related peptide (CGRP) release, a key mediator of migraine pain. The shared underlying pathway of neuroinflammation provides the conceptual bridge between Apremilast's established mechanism and this predicted new indication.

It is critical to emphasise, however, that this connection remains entirely theoretical. No preclinical studies in migraine models, translational research, or clinical trials have directly examined Apremilast for this purpose. The high TxGNN score reflects shared pathway topology within the knowledge graph rather than empirical clinical evidence. This prediction should be treated as a signal for hypothesis generation only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Australia Market Information

Apremilast is not currently registered on the Australian Register of Therapeutic Goods (ARTG). There are no TGA-approved products containing Apremilast available in Australia at the time of this report (data cutoff: 5 April 2026).

Clinicians and researchers seeking product-level information should refer to the FDA-approved Prescribing Information for Otezla® (apremilast) or equivalent internationally approved labelling.

---

## Safety Considerations

Please refer to the internationally approved Product Information (PI) for Apremilast (Otezla®) for full safety information, as there is no TGA-registered Australian PI available. Key safety signals identified from global regulatory approvals include psychiatric effects (depression, suicidal ideation), clinically significant weight loss, interactions with strong CYP3A4 inducers such as rifampicin and carbamazepine, and dose adjustment requirements in severe renal impairment (CrCl < 30 mL/min).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
At L5 evidence level with no supporting clinical trials or relevant published literature, there is no empirical basis to advance Apremilast as a migraine treatment beyond a theoretical hypothesis. The neuroinflammatory mechanism provides a plausible conceptual link, but this has not been tested in any migraine model or patient population.

**To proceed, the following is needed:**

- Preclinical studies examining Apremilast's effect on CGRP release and trigeminovascular activation in established migraine animal models
- A systematic review of PDE4 expression within trigeminal ganglia and its role in migraine neuroinflammation
- Pharmacovigilance signal review: analysis of real-world adverse event and outcomes data for patients receiving Apremilast for approved indications (PsA/psoriasis) to identify any spontaneous migraine-related reports
- Detailed mechanism of action data (full DrugBank entry) to strengthen the mechanistic rationale
- TGA registration pathway scoping, only if preclinical data emerges to justify a clinical development programme in Australia

> ⚠️ **Disclaimer:** This report is generated for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. All content should be interpreted in the context of the data cutoff date (5 April 2026).
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

